223PThe impact of neoadjuvant dual HER2 targeting with pertuzumab and trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience.

Saved in:
Bibliographic Details
Title: 223PThe impact of neoadjuvant dual HER2 targeting with pertuzumab and trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience.
Authors: Forner, S1 (AUTHOR), Sim, V R1 (AUTHOR), Glendenning, J L1 (AUTHOR), Burcombe, R1 (AUTHOR)
Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p. 1 Chart.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdy270.218